Despite the initial reports showing beneficial effects of dopaminergic treatment on speech in Parkinson's disease (PD), more recent studies based upon valid measurements have not approved any improvement of speech performance under pharmacotherapy. The aim of this study was to analyze the effect of treatment initiation on the progression of speech impairment in PD, using novel evaluation criteria. Nineteen de novo patients with PD were tested and retested within 2 years after the introduction of antiparkinsonian therapy. As controls, 19 age-matched individuals were recorded. Speech examination included sustained phonation, fast syllable repetition, reading text, and monolog. Quantitative acoustic analyses of the key aspects of speech based on Gaussian kernel distribution, statistical decision-making theory, and healthy speech observation were used to assess the improvement or deterioration of speech. A trend for speech performances to improve was demonstrated after treatment mainly in quality of voice, intensity variability, pitch variability, and articulation. The treatment-related improvement differed in various aspects of speech for individual PD patients. Improvements in vowel articulation and pitch variability correlated with treatment-related changes in bradykinesia and rigidity, whereas voice quality and loudness variability improved independently. Using a novel approach of acoustic analysis and advanced statistics, improvements in speech performance can be demonstrated in PD patients after the introduction of antiparkinsonian therapy. Moreover, changes in speech articulation and pitch variability appear to be related with dopaminergic responsiveness of bradykinesia and rigidity. Therefore, speech may be a valuable marker of disease progression and treatment efficacy in PD.

Department of Circuit Theory Faculty of Electrical Engineering Czech Technical University Prague Technická 2 16000 Prague 6 Czech Republic

Zobrazit více v PubMed

Clin Neurol Neurosurg. 2007 Jul;109(6):495-500 PubMed

Eur Neurol. 1977;15(1):34-9 PubMed

Mov Disord. 2008 Apr 30;23(6):824-9 PubMed

J Commun Disord. 2002 May-Jun;35(3):217-39 PubMed

J Neurol Neurosurg Psychiatry. 2000 Sep;69(3):319-24 PubMed

Laryngoscope. 1999 Aug;109(8):1287-94 PubMed

Int J Lang Commun Disord. 2000 Jul-Sep;35(3):407-18 PubMed

Nature. 1971 Jun 4;231(5301):315-6 PubMed

NeuroRehabilitation. 2002;17(3):237-46 PubMed

Arch Neurol. 2001 Oct;58(10):1611-5 PubMed

J Speech Hear Disord. 1963 Aug;28:221-9 PubMed

Acta Psychol (Amst). 1998 Nov;100(1-2):71-84 PubMed

J Speech Lang Hear Res. 1997 Jun;40(3):615-26 PubMed

J Acoust Soc Am. 2008 Sep;124(3):1638-52 PubMed

J Acoust Soc Am. 2011 Jan;129(1):350-67 PubMed

IEEE Trans Biomed Eng. 2009 Apr;56(4):1015 PubMed

J Speech Lang Hear Res. 2010 Feb;53(1):114-25 PubMed

Mov Disord. 2008 Mar 15;23(4):574-80 PubMed

Parkinsonism Relat Disord. 1997 Apr;3(2):111-6 PubMed

J Voice. 1997 Sep;11(3):314-20 PubMed

J Voice. 2011 Jul;25(4):467-72 PubMed

J Neurol Neurosurg Psychiatry. 1971 Dec;34(6):679-81 PubMed

Lancet Neurol. 2004 Sep;3(9):547-56 PubMed

Neurology. 2000 Jan 25;54(2):458-62 PubMed

J Gerontol. 1990 Mar;45(2):P35-45 PubMed

Mov Disord. 2009 Apr 15;24(5):716-22 PubMed

J Commun Disord. 1975 Sep;8(3):271-9 PubMed

Folia Phoniatr Logop. 2005 Jan-Feb;57(1):28-37 PubMed

J R Soc Interface. 2011 Jun 6;8(59):842-55 PubMed

J Commun Disord. 2000 Jan-Feb;33(1):59-88 PubMed

Folia Phoniatr (Basel). 1993;45(4):157-64 PubMed

Biomed Eng Online. 2007 Jun 26;6:23 PubMed

Neurology. 1973 Aug;23(8):865-70 PubMed

J Neurol Neurosurg Psychiatry. 1992 Mar;55(3):181-4 PubMed

J Fluency Disord. 2003 Spring;28(1):55-70 PubMed

J Speech Lang Hear Res. 2007 Aug;50(4):899-912 PubMed

Neurology. 1982 Jul;32(7):749-54 PubMed

Arch Neurol. 2005 Mar;62(3):378-82 PubMed

N Engl J Med. 2006 Aug 31;355(9):896-908 PubMed

J Speech Hear Disord. 1978 Feb;43(1):47-57 PubMed

Ann Otol Rhinol Laryngol. 1995 Mar;104(3):197-202 PubMed

Mov Disord. 2011 Aug 15;26(10):1951-2 PubMed

Mov Disord. 2011 Jan;26(1):59-64 PubMed

J Neural Transm (Vienna). 2010 Feb;117(2):197-205 PubMed

Behav Neurol. 1998;11(3):131-137 PubMed

Phys Ther. 2008 Jun;88(6):733-46 PubMed

Acta Neurol Belg. 2006 Mar;106(1):19-22 PubMed

J Commun Disord. 1986 Oct;19(5):347-66 PubMed

J Am Geriatr Soc. 1970 Feb;18(2):142-51 PubMed

Ann Otol Rhinol Laryngol. 2002 Jan;111(1):15-20 PubMed

J Speech Hear Res. 1969 Jun;12(2):246-69 PubMed

Med Sci Monit. 2005 Mar;11(3):CR109-16 PubMed

Articulatory undershoot of vowels in isolated REM sleep behavior disorder and early Parkinson's disease

Short-term effect of dopaminergic medication on speech in early-stage Parkinson's disease

Speech Biomarkers in Rapid Eye Movement Sleep Behavior Disorder and Parkinson Disease

Comparative analysis of speech impairment and upper limb motor dysfunction in Parkinson's disease

Speech disorders in Parkinson's disease: early diagnostics and effects of medication and brain stimulation

Effects of dopaminergic replacement therapy on motor speech disorders in Parkinson's disease: longitudinal follow-up study on previously untreated patients

A distinct variant of mixed dysarthria reflects parkinsonism and dystonia due to ephedrone abuse

Acoustic evaluation of short-term effects of repetitive transcranial magnetic stimulation on motor aspects of speech in Parkinson's disease